


CLAIMS

WHAT IS CLAIMED IS:

1. A pharmaceutical solid dosage form for oral delivery of a compound of Formula (I),



Formula (I),

wherein the solid dosage form comprises a solid dispersion comprising the compound of Formula (I) and one or more pharmaceutically acceptable excipients,

wherein the solid dispersion comprises a pharmaceutically acceptable polymer which is hypromellose acetate succinate (HPMCAS);

and the solid dosage form is a capsule or a tablet.

2. The solid dosage form of claim 1, wherein the solid dosage form is a tablet.
3. The solid dosage form of claim 1 or 2, wherein the one or more pharmaceutically acceptable excipients comprise a binder, a filler, a disintegrant and a lubricant.
4. The solid dosage form of claim 3, wherein the one or more pharmaceutically acceptable excipients further comprise a glidant.
5. The solid dosage form of any one of claims 1 to 4, wherein the solid dispersion is present in an amount from 15% to 50% by weight of the solid dosage form.
6. The solid dosage form of any one of claims 1 to 5, wherein the pharmaceutically acceptable polymer is present in an amount from 15% to 35% by weight of the solid dosage form.
7. The solid dosage form of any one of claims 1 to 6, wherein the compound of Formula (I) is present in an amount from 1% to 15% by weight of the solid dosage form.
8. The solid dosage form of any one of claims 1 to 6, comprising 5 mg to 100 mg of the compound of Formula (I).
9. The solid dosage form of any one of claims 1 to 8, comprising about 10 mg of the compound of Formula (I).
10. The solid dosage form of any one of claims 1 to 8, comprising about 40 mg of the compound of Formula (I).

11. The solid dosage form of any one of claims 1 to 10, wherein the one or more excipients comprise microcrystalline cellulose, mannitol, croscarmellose sodium and magnesium stearate.

12. The solid dosage form of claim 1, wherein the solid dosage form comprises, by weight of the solid dosage form:

- (a) 15% to 50% of a solid dispersion comprising the compound of Formula (I) and HPMCAS;
- (b) 20% to 50% of a microcrystalline cellulose;
- (c) 20% to 40% of a mannitol;

(d) 1.0% to 5.0% of a croscarmellose sodium; and

(e) 0.25% to 1.25% of magnesium stearate.

13. A solid dosage form of any one of claims 1 to 12 for use in treating von Hippel-Lindau (VHL) disease in a subject.

14. Use of a solid dosage form of any one of claims 1 to 12 in the manufacture of a medicament for the treatment of von Hippel-Lindau (VHL) disease in a subject.

15. The solid dosage form for use of claim 13 or the use of claim 14, wherein the subject also suffers from a hemangioblastoma, a pheochromocytoma, a pancreatic neuroendocrine tumor or renal cell carcinoma.

16. The solid dosage form for use of claim 13 or the use of claim 14, wherein the subject suffers from renal cell carcinoma.

17. A solid dosage form of any one of claims 1 to 12 for use in treating renal cell carcinoma in a subject.

18. Use of a solid dosage form of any one of claims 1 to 12 in the manufacture of a medicament for the treatment of renal cell carcinoma.

19. The solid dosage form for use of claim 15, 16 or 17 or the use of claim 15, 16 or 18 wherein the renal cell carcinoma is clear cell renal cell carcinoma.